Previous studies showing a partial reduction of arthritis severity by treatment with R406 or fostamatinib in animal models of arthritis, including the K/BxN serum–transfer arthritis model (28,29), raised the possibility that the lack of Syk activity can be partially compensated for by another, Syk-independent mechanism. The gene discussed is SYK; the disease is arthritic joint disease.